Results 41 to 50 of about 766,404 (301)
Molecular Psychiatry, 2021 Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined.
L. Sforzini +60 more
semanticscholar +1 more source
Nortriptyline for Treatment-Resistant Depression [PDF]
The Journal of Clinical Psychiatry, 2003 Up to 30% of patients with major depression fail to respond to an antidepressant trial, with most taking a selective serotonin reuptake inhibitor (SSRI) as initial treatment. While the tricyclic antidepressants might be effective for SSRI nonresponders, they have been relegated to third- and fourth-line treatment.
Andrew A, Nierenberg +8 more
openaire +2 more sources
Treatment-Resistant Depression in Poland—Epidemiology and Treatment [PDF]
Journal of Clinical Medicine, 2022 (1) Background: Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders worldwide. Although several antidepressant drugs have been developed, up to 30% of patients fail to achieve remission, and acute remission rates decrease with the number of treatment steps required.
Piotr Gałecki +3 more
openaire +2 more sources
Antidepressant discontinuation in treatment resistant depression
Contemporary Clinical Trials Communications, 2019 Treatment-resistant depression (TRD) is a growing problem in psychiatric practice with some 15–20% of depressed patients becoming chronically depressed and perhaps as many as 40% in tertiary settings.
Ziad A. Ali +2 more
doaj +1 more source
American Journal of Psychiatry, 2019 OBJECTIVE About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective ...
V. Popova +15 more
semanticscholar +1 more source
BMC Medicine, 2023 Background Major depressive disorder (MDD) has a significant impact on global burden of disease. Complications in clinical management can occur when response to pharmacological modalities is considered inadequate and symptoms persist (treatment-resistant
V. Karageorgiou +6 more
semanticscholar +1 more source
Psychiatry Research, 2023 Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking ...
M. Pettorruso +27 more
semanticscholar +1 more source
Closed-loop neuromodulation in an individual with treatment-resistant depression
Nature Medicine, 2021 Deep brain stimulation is a promising treatment for neuropsychiatric conditions such as major depression. It could be optimized by identifying neural biomarkers that trigger therapy selectively when symptom severity is elevated.
K. Scangos +12 more
semanticscholar +1 more source
The Individual and Societal Burden of Treatment-Resistant Depression: An Overview
Psychiatric Clinics of North America, 2023 Major depressive disorder is characterized by depressed mood and/or anhedonia with neurovegetative symptoms and neurocognitive changes affecting an individual's functioning in multiple aspects of life.
K. M. Baig-Ward, M. Jha, M. Trivedi
semanticscholar +1 more source
Case Report: Use of Subcutaneous Midazolam During an Episode of Catatonia
Frontiers in Psychiatry, 2021 Midazolam is a benzodiazepine (BZD) mainly used in anesthetic induction due to its pharmacokinetic features. Its place in the therapeutic management of catatonia remains to be determined. Here we present the case of a 65-year-old man who presented with a
Valentin Raymond +5 more
doaj +1 more source